Stoke Therapeutics, Inc. (STOK) — Stock Score Summary

Stoke Therapeutics, Inc. (STOK) has a MoatMap StockRank of 34/100 based on Quality (38/100), Value (34/100), and Momentum (48/100) factor scores. The current signal is SELL. Stoke Therapeutics is an early-stage biotech company focusing on RNA-based medicines. It lacks commercialized products, has high cash burn, and does not possess the validated, cash-generative CDMO model we look for in healthcare.

Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing antisense oligonucleotide (ASO) medicines to increase protein expression and treat genetic diseases caused by protein insufficiency. The company's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform aims to precisely upregulate protein levels by targeting pre-mRNA, addressing conditions like Dravet syndrome and severe epilepsies. This innovative ASO technology offers a distinct competitive moat in the precision medicine field, targeting diseases at their genetic root cause.

Key Financial Metrics

Price$29.37
Market Cap$2.0B
P/E (Forward)-9.70
Price/Book4.75
Return on Equity-45.6%
Return on Invested Capital-5.7%
Debt/Equity0.87
Gross Margin100.0%
Operating Margin-857.6%
Revenue Growth-96.1%
Free Cash Flow$-89M

Stoke Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Stoke Therapeutics, Inc.’s (STOK) StockRank?
MoatMap’s StockRank for Stoke Therapeutics, Inc. (STOK) is 34/100, with a Sell signal. It is a composite of Quality (38), Value (34), and Momentum (48) factor ranks across MoatMap’s 19,000+ stock universe.
Does Stoke Therapeutics, Inc. have an economic moat?
Stoke Therapeutics, Inc. (STOK) has a Quality factor score of 38/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Stoke Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Stoke Therapeutics, Inc. (STOK) is Sell, based on a StockRank of 34/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Stoke Therapeutics, Inc. in?
Stoke Therapeutics, Inc. (STOK) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksSTOK deep dive reportAI ChampionsHow we score stocksSense-check another stock